{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:48:16Z","timestamp":1787777296418,"version":"build-2784847793"},"reference-count":20,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>FDG-PET\u2013negative status achieved with salvage therapy is the most important determinant of favorable outcome after HSCT, for patients with R\/R cHL. Our modified Bv+Bs salvage regimen led to deep metabolic responses in the majority of patients, establishing a bridge to transplant.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000123","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T16:45:26Z","timestamp":1557852326000},"page":"1546-1552","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8508-2524","authenticated-orcid":false,"given":"M.","family":"Picardi","sequence":"first","affiliation":[{"name":"Department of Advanced Biomedical Sciences and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-231X","authenticated-orcid":false,"given":"R.","family":"Della Pepa","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-4263","authenticated-orcid":false,"given":"C.","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2714-5109","authenticated-orcid":false,"given":"N.","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4984-9238","authenticated-orcid":false,"given":"C.","family":"Mortaruolo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-0729","authenticated-orcid":false,"given":"F.","family":"Trastulli","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5132-1221","authenticated-orcid":false,"given":"M. G.","family":"Rascato","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-5499","authenticated-orcid":false,"given":"I.","family":"Cappuccio","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5845-3446","authenticated-orcid":false,"given":"M.","family":"Raimondo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-6048","authenticated-orcid":false,"given":"M.","family":"Memoli","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-7176","authenticated-orcid":false,"given":"M.","family":"Monteverde","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-220X","authenticated-orcid":false,"given":"M.","family":"Mascolo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2563-4125","authenticated-orcid":false,"given":"F.","family":"Pane","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"issue":"9","key":"2019112007005064500_B1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/2040620718786833","article-title":"Update on the role of brentuximab vedotin in classical Hodgkin lymphoma","volume":"9","author":"Tomassetti","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"2019112007005064500_B2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019112007005064500_B3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/bjh.14449","article-title":"Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma","volume":"180","author":"Kalac","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2019112007005064500_B4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019112007005064500_B5","article-title":"The Bbv regimen: a phase II study with bendamustine plus brentuximab vedotin in Hodgkin lymphoma and CD30+ peripheral T-cell lymphoma in first salvage setting [abstract]","volume":"130","author":"Stefoni","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019112007005064500_B6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(17)30913-0","article-title":"Salvage regimens for Hodgkin\u2019s lymphoma in the brentuximab vedotin era","volume":"19","author":"Vitolo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019112007005064500_B7","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019112007005064500_B8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.12120","article-title":"Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma","volume":"160","author":"Corazzelli","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"2019112007005064500_B9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2019112007005064500_B10","article-title":"Brentuximab vedotin in combination with bendamustine in relapsed or refractory hodgkin lymphoma: a retrospective analysis on 23 pediatric patients or young adults [abstract]","volume":"130","author":"Vinti","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2019112007005064500_B11","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1074\/jbc.M510026200","article-title":"Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates","volume":"281","author":"Sutherland","year":"2006","journal-title":"J Biol Chem"},{"issue":"23","key":"2019112007005064500_B12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2479.2479","article-title":"Continuous exposure to bendamustine (BDM) results in stable upregulation of CD30 and increased sensitivity to brentuximab vedotin (BV) in tumor cells of Hodgkin lymphoma (HL) [abstract]","volume":"126","author":"De Filippi","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019112007005064500_B13","doi-asserted-by":"crossref","first-page":"e40342","DOI":"10.1371\/journal.pone.0040342","article-title":"Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine","volume":"7","author":"Beeharry","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2019112007005064500_B14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2019112007005064500_B15","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2019112007005064500_B16","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019112007005064500_B17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019112007005064500_B18","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019112007005064500_B19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019112007005064500_B20","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/9\/1546\/784588\/advancesadv2019000123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/9\/1546\/784588\/advancesadv2019000123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T07:03:09Z","timestamp":1574233389000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/9\/1546\/247048\/Brentuximab-vedotin-followed-by-bendamustine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000123","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]}}}